Direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and bioprosthesis: a systematic review and meta-analysis

Back

ESC Professional Premium Access

Direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and bioprosthesis: a systematic review and meta-analysis

Session: Oral anticoagulation in patients with atrial fibrillation

Topic: Anticoagulants

Speaker: Ms P. Guardia Martinez (Malaga, ES)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Ms Paula Guardia Martinez

Quironsalud Malaga Hospital, Malaga (Spain)

1 presentation

0 follower

7 more presentations in this session

Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study

Speaker: Doctor M. Abou Kaoud (Tel Aviv, IL)

Access

Abstract

Slides

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Speaker: Mr M. Grymonprez (Gent, BE)

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

Speaker: Doctor S. Deitelzweig (New Orleans, US)

Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

Speaker: Doctor S. Patel (Boston, US)

Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis

Speaker: Doctor T. Chao (Taipei, TW)

Access the full session

Oral anticoagulation in patients with atrial fibrillation

Speakers: Ms P. Guardia Martinez, Doctor M. Abou Kaoud, Mr M. Grymonprez, Doctor S. Deitelzweig, Doctor S. Patel...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources